Drug Trial Radar · NCT04979572
A Phase I Study of TS-172 in Healthy Adult Subjects (Single and Multiple Doses)
Last checked: Nov 19, 2026Latest source record: Feb 28, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
41
Actual
Start
Aug 16, 2021
Primary completion
Jan 26, 2022
Study completion Jan 26, 2022
Sponsor
- Lead sponsor
- Taisho Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jul 28, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Basic science
- FDA-regulated drug
- No
- Who can join
- Male only, from 20 years, up to 39 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
A Phase 1, Single-Center, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Single Ascending and Multiple Dose of TS-172 in Healthy Adult Subjects
Conditions
- Healthy Adult Subjects
Interventions
TS-172Drug
* Single doses of TS-172 10 mg, 30 mg, 90 mg, 270 mg before breakfast in each period (only 30 mg administered before breakfast and fasting) * Multiple dose of TS-172 90 mg before breakfast and dinner
PlaceboDrug
* Single doses of TS-172 placebo before breakfast in each period (only placebo administered before breakfast and fasting in step 2) * Multiple dose of TS-172 placebo before breakfast and dinner
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of treatment-emergent adverse events (TEAEs) and serious AEs (SAEs)Time frame: Part A (Step 1): Day 1 up to Day 8, Part A (Step 2, 3, 4): Day 1 up to Day 4, Part B: Day 1 up to Day 11
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Taisho Pharmaceutical Co., Ltd selected site
Toshima-ku, Japan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.